Pancreatic cancer is an aggressive and intractable malignancy with high mortality. This is due in part to a high resistance to chemotherapeutics and radiation treatment conferred by diverse regulatory mechanisms. Among these, constituents of the nuclear ...

Scientists at Mount Sinai have developed a novel technology for simultaneously analyzing the functions of hundreds of genes with resolution reaching the single cell level. The technology relies on ...

Cholangiocarcinoma (CCA) is a severe and mostly intractable adenocarcinoma of biliary epithelial cells. A typical feature of CCA is its highly desmoplastic microenvironment containing fibrogenic connective tissue and an abundance of immune cells (T ...

According to the 2010 World Health Organization (WHO) classification [1], pancreatic intraduc- tal neoplasms are divided into intraductal papillary mucin- ous neoplasm (IPMN) and ITPN. ... ... ITPN was first designated by Yamaguchi et al. [2] and was ...

A Division of Gastroenterology Grand Rounds presented by Suresh T. Chari, MD, Division of Gastroenterology and Hepatology, Mayo Clinic.

Fadi Braiteh, MD, and John L. Marshall, MD, provide insight regarding dosing and administration strategies with nab-paclitaxel/gemcitabine therapy in pancreatic cancer.

Type 1: IgG4 Autoimmune Pancreatitis systematic disease Type 2: Not IGG4. Localized to Pancreas only.